Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-05-03
2005-05-03
Wehbé, Anne M. (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093200, C424S184100, C424S185100, C424S189100, C435S235100, C435S320100
Reexamination Certificate
active
06887464
ABSTRACT:
The present invention provides particles for the presentation of haptens for the purpose of eliciting an immune response. The amino acid sequences of the monomers which make up the particles are derived from duck hepatitis B virus core protein. The particles may also deliver nucleic acids. The nucleic acids may be delivered for the purpose of enhancing an immune response, or for other purposes such as gene therapy.
REFERENCES:
patent: 4356270 (1982-10-01), Itakura
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4563423 (1986-01-01), Murray et al.
patent: 4882145 (1989-11-01), Thornton et al.
patent: 5023243 (1991-06-01), Tullis
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5723335 (1998-03-01), Hutcherson et al.
patent: 6025341 (2000-02-01), Wands et al.
patent: 6231864 (2001-05-01), Berkett
patent: 0 092 574 (1992-04-01), None
patent: 07252300 (1995-10-01), None
patent: WO 9526204 (1995-10-01), None
patent: WO 9840100 (1998-09-01), None
Mason et al., Virus of Pekin Ducks with Structural and Biological Relatedness to Human Hepatitis B Virus, Dec. 1980. Journal of Virology, vol. 36, No. 3, pp. 829-836.*
Bodey et al., Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy, 2000, Anticancer Research, vol. 20, pp. 2665-2676.*
Dallal, MD, et al., Immunotherapy of Metastasis, Apr. 2001, Surgical Oncology Clinics of North America, vol. 10, No. 2, pp. 433-447.*
Yang et al. Capsid assembly and involved function analysis of twelve core protein mutants of duck hepatitis B virus vol. 68, No. 1 pp. 338-345 1994.*
Weizsacker et al. Inhibiton of viral replication by genetically engineered mutants of the duck hepatits B virus core protein pp. 294-299 vol. 24, No. 2, 1996.*
Kock et al. Duck hepatitis B virus nucleocapsids formed by N-Terminally extended or C-Terminally truncated core proteins disintegrate during viral DNA maturation vol. 72, No. 11 1998.*
Masonn et al. Virus of pekin ducks with structural and biological relatedness to human hepatitis B virus vol. 36, No. 3 pp. 829-836.*
Schodel et al. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes pp. 91-96 1996.*
Beaucage et al., 22(20) Tetrahedron Letters 1859—62 (1981).
Boggs et al., 7 Antisense & Nucl. Acid Drug Devel. 461-71 (1997).
Bringas, 118 J. Structural Biol. 189-96(1997).
Carson et al., 186(10) J. Exp. Med. 1621-22 (1997).
Cookson et al., 275 Science 41-42 (1997).
Davis et al., 160 J. Immunol. 870-76 (1998).
Gaffney et al., 29(22) Tetrahedron Letters 2619-22 (1988).
Garegg et al., 27(34) Tetrahedron Letters 4051-54 (1986).
Gilewski et al., 6 Clin. Cancer Res. 1693-1701 (2000).
Gong et al., 97(6) PNAS 2715-18 (2000).
Goodchild, 1(3) Bioconjugate Chem. 165-87 (1990).
Griffiths et al., 67(6) J. Virol. 3191-98 (1993).
Harris et al., 77 Immunol. 315-21 (1992).
Holmberg et al., 25 Bone Marrow Transplant. 1233-41 (2000).
Krieg et al., 374 Nature 546-49 (1995).
Krieg et al., 6 Antisense & Nucl. Acid Drug Devel. 133-39 (1996).
Lipford et al., 27 Eur. J. Immunol. 2340-44 (1997).
Lipford et al., 27 Eur. J. Immunol. 3420-36 (1997).
Milich, 2 Seminars in Immunol. 307-15 (1990).
Milich et al., 754 Ann. NY Acad. Sci. 187-201 (1995).
Pisetsky, 5 Immunity 303-10 (1996).
Raychaudhuri et al., 16 Nature Biotech. 1025-31 (1998).
Schirmbeck et al., 152 J. Immunol. 1110-19 (1994).
Schirmbeck et al., 155 J. Immunol. 4676-84 (1995).
Schödel et al., 66(1) J. Virol. 106-14 (1992).
Schödel et al., 268(2) J. Biol. Chem. 1332-37 (1993).
Schödel et al., 11(2) Vaccine 143-48 (1993).
Schödel et al., 11(2) Int'l Rev. Immunol. 153-165 (1994).
Schödel et al., 98 Behring Inst. Mitt. 114-19 (1997).
Simons et al., 59 Cancer Res. 5160-68 (1999).
Sparwasser et al., 27 Eur. J. Immunol. 1671-79 (1997).
Sparwasser et al., 28 Eur. J. Immunol. 2045-54 (1998).
Stacey et al., 157 J. Immunol. 2116-22 (1996).
Sun et al., 187 (7) J. Exp. Med. 1145-50 (1998).
Uhlmann et al., 90(4) 544-84 (1990).
Wynne et al., 3 Mol. Cell. 771-80 (1990).
Zimmermann et al., 160 J. Immunol. 3627-30 (1998).
Coleman Timothy P.
Peterson Darrell L.
BioCache Pharmaceuticals, Inc.
Li Q. Janice
Preston Gates Ellis & Rouvelas Meeds LLP
Wehbe Anne M.
LandOfFree
Advanced antigen presentation platform does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Advanced antigen presentation platform, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Advanced antigen presentation platform will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3411566